Posted by Michael Wonder on 09 Sep 2020
Clarity Pharmaceuticals announces the US FDA grants rare paediatric disease designation to 64 Cu sartate, a diagnostic for the clinical management of neuroblastoma
9 September 2020 - Clarity Pharmaceuticals is pleased to announce that the U.S. FDA has granted rare paediatric disease designation to 64 Cu sartate, a diagnostic for the clinical management of neuroblastoma.
The FDA defines a “rare paediatric disease” as a serious or life-threatening disease primarily affecting individuals aged 18 years or younger that impacts fewer than 200,000 people in the United States.
The program is intended to facilitate development of new drugs and biologics for the prevention and treatment of rare paediatric diseases.
